538 related articles for article (PubMed ID: 11776756)
1. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
3. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Bhatia J; Morris R; Begent RH
Int J Radiat Biol; 2002 May; 78(5):407-15. PubMed ID: 12020430
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
Casey JL; King DJ; Chaplin LC; Haines AM; Pedley RB; Mountain A; Yarranton GT; Begent RH
Br J Cancer; 1996 Nov; 74(9):1397-405. PubMed ID: 8912535
[TBL] [Abstract][Full Text] [Related]
5. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
Stein R; Juweid M; Mattes MJ; Goldenberg DM
Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
[TBL] [Abstract][Full Text] [Related]
6. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.
Buchsbaum DJ; Lawrence TS; Roberson PL; Heidorn DB; Ten Haken RK; Steplewski Z
Int J Radiat Oncol Biol Phys; 1993 Mar; 25(4):629-38. PubMed ID: 8454481
[TBL] [Abstract][Full Text] [Related]
8. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry.
Flynn AA; Pedley RB; Green AJ; Dearling JL; El-Emir E; Boxer GM; Boden R; Begent RH
Radiat Res; 2003 Feb; 159(2):182-9. PubMed ID: 12537523
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.
Ugur O; Kostakoglu L; Hui ET; Fisher DR; Garmestani K; Gansow OA; Cheung NK; Larson SM
Nucl Med Biol; 1996 Jan; 23(1):1-8. PubMed ID: 9004907
[TBL] [Abstract][Full Text] [Related]
10. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan.
D'Arienzo M; Cicone F; Chiacchiararelli L; Coniglio A; Delaloye AB; Scopinaro F
Cancer Biother Radiopharm; 2012 Mar; 27(2):124-33. PubMed ID: 22283680
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
14. Optimal timing of administration of hyperthermia in combined radioimmunotherapy.
Kinuya S; Yokoyama K; Hiramatsu T; Konishi S; Watanabe N; Shuke N; Aburano T; Bunko H; Michigishi T; Tonami N
Cancer Biother Radiopharm; 2000 Aug; 15(4):373-9. PubMed ID: 11041022
[TBL] [Abstract][Full Text] [Related]
15. A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection.
Flynn AA; Green AJ; Pedley RB; Boxer GM; Dearling J; Watson R; Boden R; Begent RH
Cancer; 2002 Feb; 94(4 Suppl):1249-57. PubMed ID: 11877753
[TBL] [Abstract][Full Text] [Related]
16. Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy.
Mayer R; Dillehay LE; Shao Y; Zhang YG; Song S; Bartholomew RM; Mackenson DG; Williams JR
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):147-57. PubMed ID: 7721611
[TBL] [Abstract][Full Text] [Related]
17. Theoretical study of the influence of a heterogeneous activity distribution on intratumoral absorbed dose distribution.
Bao A; Zhao X; Phillips WT; Woolley FR; Otto RA; Goins B; Hevezi JM
Med Phys; 2005 Jan; 32(1):200-8. PubMed ID: 15719971
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery.
Kim JC; Roh SA; Koo KH; Ryu JH; Hong HK; Oh SJ; Ryu JS; Kim HJ; Bodmer WF
Int J Cancer; 2002 Feb; 97(4):542-7. PubMed ID: 11802220
[TBL] [Abstract][Full Text] [Related]
19. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
20. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]